Cladis Investment Advisory’s Bristol-Myers Squibb BMY Stock Holding History

Cladis Investment Advisory’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$928K	Sell	15,300 -50	-0.3%	-$2.92K	0.51%	63
2025 Q4	$828K	Sell	15,350 -13,757	-47%	-$662K	0.45%	69
2025 Q3	$1.31M	Sell	29,107 -700	-2%	-$32.7K	0.75%	43
2025 Q2	$1.38M	Buy	29,807 +2,000	+7%	+$98.2K	0.86%	35
2025 Q1	$1.7M	Hold	27,807	–	–	1.23%	22
2024 Q4	$1.57M	Sell	27,807 -1,700	-6%	-$95K	1.12%	25
2024 Q3	$1.53M	Sell	29,507 -29	-0.1%	-$1.36K	1.06%	25
2024 Q2	$1.23M	Buy	29,536 +383	+1%	+$17.1K	0.89%	34
2024 Q1	$1.58M	Buy	29,153 +350	+1%	+$17.8K	1.16%	22
2023 Q4	$1.48M	Buy	28,803 +200	+0.7%	+$10.5K	1.16%	26
2023 Q3	$1.66M	Sell	28,603 -500	-2%	-$30.6K	1.45%	16
2023 Q2	$1.86M	Buy	29,103 +86	+0.3%	+$5.77K	1.62%	13
2023 Q1	$2.01M	Sell	29,017 -333	-1%	-$23.5K	1.81%	9
2022 Q4	$2.11M	Sell	29,350 -1,218	-4%	-$91.8K	2.1%	8
2022 Q3	$2.17M	Sell	30,568 -800	-3%	-$58K	2.35%	5
2022 Q2	$2.42M	Sell	31,368 -500	-2%	-$38.1K	2.41%	2
2022 Q1	$2.33M	Sell	31,868 -800	-2%	-$53.7K	1.88%	6
2021 Q4	$2.04M	Buy	+32,668	New	+$1.92M	1.63%	13

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cladis Investment Advisory's BMY Position: Q1 2026 in Review

Cladis Investment Advisory reduced its Bristol-Myers Squibb (BMY) stake by 0.33% in Q1 2026, selling an estimated $2.92K and leaving 15,300 shares worth $928K. The position accounts for 0.51% of the portfolio, ranked #63.

Cladis Investment Advisory first reported a position in BMY in Q4 2021 and has held it in 18 quarters since. The position peaked at $2.42M in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Cladis Investment Advisory held 15,300 shares of Bristol-Myers Squibb worth $928K as of Q1 2026.
Cladis Investment Advisory sold 50 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.92K.
Bristol-Myers Squibb made up 0.51% of Cladis Investment Advisory's portfolio in Q1 2026, its #63 holding.
Cladis Investment Advisory first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 18 quarters since.
Cladis Investment Advisory's Bristol-Myers Squibb position peaked at $2.42M in Q2 2022.
2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Cladis Investment Advisory's 13F filing for Q1 2026, filed 15 May 2026.